What is the currently recommended duration of dual antiplatelet treatment in patients after coronary artery stenting, carotid artery stenting, or peripheral artery stenting?
In your opinion, are there any new trial results, drugs, or procedures in the field of thromboembolic disease that are worth particular attention?
How long would you treat a 19-year-old woman in whom acute proximal venous thromboembolism occurred as early as one month after starting oral contraception? Would you perform diagnostic workup for thrombophilia in this patient?
In which patients with atrial fibrillation and coronary stenting should we consider continuing treatment with an oral anticoagulant plus an antiplatelet agent (aspirin or clopidogrel) after the 12-month mark following the procedure?
In your opinion, are there any new trial results, drugs, or procedures in the field of thromboembolic disease that are worth particular attention?
Many patients with a history of pulmonary embolism ask about discontinuation of anticoagulant treatment. What would be your advice in such cases? What precautions would you recommend?
A patient at high thromboembolic risk had intracranial hemorrhage as an adverse effect of treatment with vitamin K antagonists. When can anticoagulation be restarted in this patient? What anticoagulants are recommended? Can low-dose low-molecular-weight heparins be started shortly after the hemorrhage?
In your opinion, are there any new trial results, drugs, or procedures in the field of thromboembolic disease that are worth particular attention?
Paget-Schroetter syndrome and subclavian vein thrombosis are very rarely discussed. Could you comment on these diseases and the risk of pulmonary embolism? Is this a risk for deep venous thrombosis of the lower extremity?
What is the current prophylaxis of venous thromboembolism in healthy long-distance travelers? What are the evidence-based recommendations?
English
Polski
Español
українська